Martin LeBlanc joined Great Point Partners’ CEO Advisory Board in 2012 and is currently on the Board of Softbox Systems, a GPP II portfolio company, and was previously a Board member of Cytovance Biologics, a GPP I portfolio company.
Mr. LeBlanc is the current CEO of Caprion Proteomics, a company in which GPP invested in 2007 and sold in 2012 for 3.4x invested capital and a 28% IRR. During the GPP investment period and while he was CEO, Caprion grew from around $100,000 of EBITDA in 2007 to nearly $9 million of EBITDA in 2012. Today, Caprion Proteomics is the leader in providing proteomics and immune monitoring services to the pharmaceutical and biotechnology industries.
Prior to Caprion, Mr. LeBlanc began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice-President of Sales & Marketing and then as General Manager following the company's acquisition by NEN Life Sciences (now part of Perkin-Elmer).
Mr. LeBlanc earned his bachelor's degree in economics from the University of Moncton prior to completing an M.A. in economics and politics at Oxford University as a Rhodes Scholar.
- Caprion Proteomics – biomarker services for pharmaceutical companies